Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | YEATS4 | O95619 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.42 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.42 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | HPD | P32754 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PLD2 | O14939 | 1/20 | 0.37 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440180 | 0.83 | GPR119 (0.52) | DRD2SLC6A4HSD11B1YEATS4KCNH2 | |
| SCHEMBL4440085 | 0.82 | YEATS4 (0.62) | DRD2YEATS4KCNH2MLLT3MLLT1 | |
| Trifluoroacetic Acid SCHEMBL4446739 | 0.82 | HPD (0.41) | DRD2SLC6A4HSD11B1YEATS4KCNH2 | |
| SCHEMBL14008573 | 0.80 | HPD (0.46) | DRD2SLC6A4HSD11B1YEATS4KCNH2 | |
| SCHEMBL6249088 | 0.79 | HSD11B1 (0.51) | HSD11B1CTSS | |
| SCHEMBL4437942 | 0.75 | YEATS4 (0.47) | DRD2SLC6A4HSD11B1YEATS4KCNH2 | |
| Hydrochloric Acid SCHEMBL5006590 | 0.74 | YEATS4 (0.46) | DRD2SLC6A4HSD11B1YEATS4KCNH2 | |
| SCHEMBL5836092 | 0.74 | HPD (0.50) | DRD2SLC6A4HSD11B1PIK3CAHPD | |
| SCHEMBL5836181 | 0.68 | HPD (0.53) | DRD2SLC6A4HSD11B1PIK3CAHPD | |
| SCHEMBL6245314 | 0.68 | OPRL1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | DRD2 4274/4885SLC6A4 3956/4885HSD11B1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.